CFO Research Results 2019

Findings from Criticaleye's CFO Retreat Research:

  • 71% of CFOs report that stakeholder engagement is becoming more complex and difficult
  • Only 8% are fully confident the senior team can respond to business model disruption
  • 96% of CFOs say their top team is too inward-looking and focused on the short-term
  • 64% say the Chair does not add value in terms of supporting the executive team
  • Building alignment in the senior team is where CFOs say they are falling short

Click here to watch Phil Smith, Chair, Innovate UK (& Criticaleye Board Mentor); Dame Alison Carnwath, Non-executive Director, BP; Vindi Banga, Senior Independent Director, GSK; Mike Evans, Chair, Just Eat; and Tony Hayward, Chair, Glencore share their views on where the CFO is adding value. 




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Inspiring Leaders Podcast: Su...

Martin Balaam, CEO of Pimberly and Jacqui Summons, NED/Fractional CHRO join Criticaleye's Senior Editor, Jacob Ambrose Willson to explore the demands of private equity ownership from driving value creation and manag...

Click here to download this insight
Bringing Appreciation to Life

When it comes to employee appreciation, the most successful organisations find ways to address a wide range of their employees’ needs. This report by Criticaleye Partner Reward Gateway | Edenred explores...

Inspiring Leaders Podcast: Fr...

Tea Colaianni, Senior Independent Director at Watches of Switzerland and portfolio Non-Executive Director, shares her journey from Chief People Officer to the Boardroom and the unique strengths HR leaders bring as NEDs....


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 443




IBM Consulting Lightsource bp Drax Group plc British Land Worldpay FTSE Women Leaders Review AlixPartners Workday NatWest Group Accenture Concentrix Google Legal & General Hitachi Solutions London Stock Exchange Group Salesforce E.ON UK Palo Alto Networks Aldermore Group Eightfold AI NATS Rolls-Royce GlaxoSmithKline plc